Impact Of Rising Pneumonia Cases On The Growth Of Market: Strategic Insights Driving Pulmonary Or Respiratory Drug Delivery Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Pulmonary Or Respiratory Drug Delivery Market Size By 2025?
The market size of pulmonary or respiratory drug delivery has seen robust growth over the past few years. It is projected to expand from $69.83 billion in 2024 to $75.67 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.4%. The surge in growth during the historic period is due to the increasing frequency of asthma, the escalating use of advanced inhalation devices, an uptick in worldwide healthcare spending, heightened consciousness about respiratory diseases, and a rising number of allergy-related conditions.

How Big Is the Pulmonary Or Respiratory Drug Delivery Market Size Expected to Grow by 2029?
In the coming years, substantial growth is anticipated in the pulmonary or respiratory drug delivery market, with its value expected to reach "$105.32 billion in 2029 with a compound annual growth rate (CAGR) of 8.6%. This surge in the forecast period is due to factors such as increased interest in personalized medicine, the growing occurrence of chronic respiratory diseases, a heightened focus on telemedicine, more substantial investments in healthcare infrastructure, and the e-commerce expansion in the pharmaceutical sector. Key trends that will feature in the forecast period include the progression of particle engineering, the creation of advanced nebulizers, the development of liposomal formulations, the advancement of computational fluid dynamics, and the emergence of smart inhalers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

Which Key Market Drivers Powering Pulmonary Or Respiratory Drug Delivery Market Expansion and Growth?
The rise in pneumonia cases is projected to stimulate expansion in the pulmonary or respiratory drug delivery market. As a lung infection, pneumonia results in the inflammation of air sacs potentially filled with fluid or pus, leading to symptoms such as coughing, fever, and breathing difficulties. Influencing factors of pneumonia's prevalence include the ageing population, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. Delivering medication directly to the lungs, such as antibiotics, bronchodilators, or anti-inflammatory agents makes pulmonary or respiratory drug delivery a useful form of treatment for pneumonia. It offers quicker and more powerful measures to relieve symptoms, cut down inflammation, remove infections and improve respiratory function, ultimately accelerating recovery and fending off further complications. To illustrate, the Centre for Tropical Medicine and Global Health, a healthcare research institution based in the UK, reported in November 2023 that cases of pneumonia in Kenya had dramatically risen, amounting to 793,864 in 2022/2023. Therefore, pneumonia's growing prevalence bolsters the market for pulmonary or respiratory drug delivery.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What Are the Key Trends Driving Pulmonary Or Respiratory Drug Delivery Market Growth?
Leading players in the pulmonary and respiratory drug delivery market concentrate on technological breakthroughs like intricate drug delivery systems, which improve treatment efficiency and patient adherence. These sophisticated systems aid in targeted administration and controlled release of therapeutic agents, thus augmenting drug effectiveness and patient results. For example, in July 2023, Viatris Inc., a healthcare company from the US manufacturing generic and branded pharmaceuticals, along with Kindeva Drug Delivery L.P., another US-based firm that specializes in drug delivery, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This aerosol, approved by the US-based government body, the Food and Drug Administration, is the inaugural generic version of AstraZeneca's Symbicort, and is a measured-dose inhaler, assembling budesonide and formoterol to treat asthma and chronic obstructive pulmonary disease. It is dispensed in two potencies of 80 micrograms and 160 micrograms with 4.5 micrograms of formoterol.

What Are the Emerging Segments in the Pulmonary Or Respiratory Drug Delivery Market?
The pulmonary or respiratory drug delivery market covered in this report is segmented -

1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Who Are the Global Leaders in the Pulmonary Or Respiratory Drug Delivery Market?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Which are the Top Profitable Regional Markets for the Pulmonary Or Respiratory Drug Delivery Industry?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.